Minoxidil
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Minoxidil: Hypotrichosis simplex of the scalp
One-Sentence Summary
Minoxidil was originally used to treat hypertension (as an oral vasodilator) and alopecia (as a topical hair-regrowth treatment). The TxGNN model predicts it may be effective for hypotrichosis simplex of the scalp, a rare hereditary hair-loss disorder. Support is limited: there are no registered clinical trials and 3 small case reports, all using minoxidil in combination with other treatments.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Hypotrichosis simplex of the scalp |
| TxGNN Prediction Score | 1.0000 |
| Evidence Level | L4 |
| Canada Market Status | Marketed (marketed DINs: 9 of 10; dormant: 1) |
| Number of DINs | 10 (marketed: 9) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the data compiled for this report. Based on known information, minoxidil is an established hair-growth stimulant. Its sulfate metabolite opens potassium channels, which prolongs the anagen (growth) phase of the hair cycle and increases blood flow to the follicle. Its efficacy in common hair loss is well established.
Hypotrichosis simplex of the scalp is a rare, inherited disorder (linked to variants in the CDSN gene) in which hair density is reduced. Because minoxidil acts on hair-cycle duration and follicle perfusion, it is plausibly relevant to a condition defined by reduced hair growth.
A key caveat is that the available reports combine minoxidil with growth factors, botanical extracts, or platelet-rich plasma (PRP). This makes it impossible to attribute any benefit to minoxidil alone.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35761391 | 2022 | Case report/series | Dermatologic Therapy | Hereditary hypotrichosis simplex of the scalp treated with oral minoxidil plus growth factors |
| 39902296 | 2024 | Case report | Frontiers in Genetics | Familial case in an 8-year-old boy with a CDSN mutation, treated with botanical extracts plus minoxidil |
| 36651821 | 2023 | Case report | J Dermatol Treat | A 14-year-old patient treated with PRP injections plus topical minoxidil 2%; the report describes successful treatment of a condition with no previously satisfactory therapy |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02551446 | Men’s Hair Regrowth Treatment | Not specified | Not specified |
| 00708925 | Men’s Rogaine | Not specified | Not specified |
| 02356597 | Hair Regrowth Formula | Not specified | Not specified |
| 00514500 | Loniten 10 mg | Not specified | Not specified |
| 02529238 | Jamp Minoxidil Solution | Not specified | Not specified |
Ten valid single-ingredient licences are on record in total; none are cancelled. The list above shows five of them. The product names indicate topical hair-regrowth products and the oral Loniten tablets.
Safety Considerations
Contraindications (from knowledge-graph drug-disease links, not label text):
- Cardiovascular: myocardial infarction, coronary thrombosis, heart disease, cardiovascular disease, pericarditis, pericardial effusion, hemopericardium, cardiac tamponade
- Cerebrovascular: stroke, cerebral infarction, cerebrovascular disorder
- Blood pressure regulation: orthostatic hypotension, postural orthostatic tachycardia syndrome, multiple system atrophy
- Tumours: pheochromocytoma, sympathetic paraganglioma, and several adrenal, heart and small-intestine cancers
- Other: kidney disease, hemoglobinopathy, scalp dermatosis
Drug Interactions: The interaction database lists 100 recorded interactions. The main ones shown in the data are of moderate severity:
- Corticosteroids: hydrocortisone, triamcinolone, dexamethasone, betamethasone, budesonide, prednisolone, prednisone
- SGLT2 inhibitors: canagliflozin, dapagliflozin, empagliflozin, ertugliflozin
- Opioids and cannabinoids: morphine, opium, dronabinol, nabilone
- Others: bupropion, sapropterin
Package-insert warnings and contraindications from Health Canada have not been obtained. Please refer to the package insert for authoritative safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high and the mechanism is plausible. However, the supporting evidence consists of only three small case reports that all use minoxidil in combination with other therapies, and there are no registered trials. The condition is rare, so a cautious, evidence-building approach is appropriate. Note that the formal screening rubric rates this indication as a “Research Question” rather than a candidate for advancement.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications, which are currently a blocking gap for safety screening
- Detailed mechanism-of-action data from DrugBank
- Studies or case series that isolate the effect of minoxidil alone (for example, N-of-1 or small controlled designs)
- A safety plan for oral use in children and in patients with cardiovascular conditions
- Approved indication text and dosage-form details for the Canadian licences
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.